Assertio (ASRT)
(Delayed Data from NSDQ)
$1.52 USD
-0.10 (-6.17%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Brokerage Reports
Assertio Holdings, Inc. [ASRT]
Reports for Purchase
Showing records 1 - 20 ( 116 total )
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Expect Revenue And Earnings To Rebound In 2025 On Increased Demand For Rolvedon,Maintain $3 Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
1Q:24 Revenue Beat On Rolvedon Sales; 2024 Sales Guidance Reiterated
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Project 1Q:24 Revenue Fell 32% From 1Q:23, Due To The Decline In Indocin Sales
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
4Q:23 Revenue Beat On Rolvedon Sales; 2024 Sales Guidance Issued
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Project 4Q:23 Revenue Fell 38% From 4Q:22, Due To The Decline In Indocin Sales From Exclusivity Loss
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
New CEO Announced; Lower Estimates, Reduce Price Target To $3
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Lower Estimates And Target To $4 (From $7);Expect 2025 Earnings Rebound; Balance Sheet Solid
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
3Q23 Recap - Hitting the Reset Button; Balance Sheet Helps
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Project 3Q:23 Revenue Jumped 36% As Rolvedon Launch More Than Offset Indocin Decline From Exclusivity Loss; Maintain $7 Price Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Analyst Coverage Transition To James Sidoti; Spectrum Deal Complete
Provider: Sidoti CSR
Analyst: Research Department